BCAN - KALA AZUL and GOL are among pre market gainers
2023-03-06 08:32:34 ET
- BridgeBio Pharma ( BBIO ) +57% Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events.
- TCR2 Therapeutics ( TCRR ) +25% stock rise 41% after merger deal with Adaptimmune.
- Kala Pharmaceuticals ( KALA ) +28% .
- Avalon GloboCare ( ALBT ) +29% .
- Azul ( AZUL ) +21% .
- BYND Cannasoft Enterprises ( BCAN ) +20% .
- Armata Pharmaceuticals ( ARMP ) +20% as inhaled bacterial infection drug shows promise in lung disorder patients .
- FingerMotion ( FNGR ) +18% .
- Entera Bio ( ENTX ) +15% .
- Secoo Holding ( SECO ) +13% .
- Nyxoah ( NYXH ) +13% Announces Achievement of Key Clinical and Regulatory Milestones.
- DBV Technologies ( DBVT ) +11% .
- Ciena Corporation ( CIEN ) +11% to watch on Monday: Ciena, Apple and more.
- Markforged Holding ( MKFG ) +10% .
- Gol Linhas Aereas Inteligentes ( GOL ) +8% .
- Clene ( CLNN ) +7% Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial.
- Coherus BioSciences ( CHRS ) +6% Q4 Earnings release
- AMC Entertainment Holdings ( APE ) +5% .
- Edible Garden AG ( EDBL ) +6% .
- Atai Life Sciences ( ATAI ) +6% rises amid restructuring with ~30% job cuts.
- BioSig Technologies ( BSGM ) +5% .
- BuzzFeed ( BZFD ) +5% .
- CECO Environmental ( CECO ) +5% Q4 earnings call release
For further details see:
KALA, AZUL and GOL are among pre market gainers